JAC Advance Access originally published online on August 13, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 52, 331-344
© 2003 The British Society for Antimicrobial Chemotherapy
Review |
Properties and potential of ertapenem
1 Antibiotic Resistance Monitoring & Reference Laboratory, Central Public Health Laboratory, 61 Colindale Avenue, London NW9 5HT; 2 Department of Medical Microbiology, Barts and the London, Queen Mary’s School of Medicine and Dentistry, Turner Street, London E1 2AD; 3 Department of Clinical Microbiology, University College London Hospital, London WC1E 6DB, UK
Ertapenem is a carbapenem that shares the activity of imipenem and meropenem against most species, but is less active against non-fermenters. Activity is retained against most strains with AmpC and extended-spectrum ß-lactamases, although resistance can arise if these enzymes are combined with extreme impermeability. Resistance can also be caused by IMP, VIM, KPC and NMC carbapenemases, but again, co-requires impermeability. Although the spread of carbapenemases in the future is a concern, they are currently very rare. Given as a 1 g intravenous (iv) infusion once daily, ertapenem has a plasma half-life of 
4 h in healthy volunteers, and a Cmax of 155 mg/L and 13 mg/L for total and free drug, respectively. Excretion is largely renal, divided equally between native drug and an open-ring derivative. Trials show equivalence to piperacillin/tazobactam or ceftriaxone in (a) intra-abdominal infections, (b) community-acquired pneumonia, (c) acute pelvic infections, (d) skin and skin structure infections and (e) complicated urinary tract infections. The USA licence grants all these five indications; the EU licence grants the first three. Further potential uses include home iv therapy, directed therapy against Enterobacteriaceae with AmpC or extended-spectrum cephalosporinases, and tentatively, surgical prophylaxis. Widening the usage of carbapenems raises public health concerns, somewhat allayed by the continued rarity of carbapenemases after 17 years of imipenem use, and by the fact that carbapenemases occur mostly in non-fermenters outside the spectrum of ertapenem, and co-require impermeability to confer resistance in Enterobacteriaceae. Nevertheless, if ertapenem is to be used widely, its effects on the resistance ecology need to be monitored carefully.
Keywords: carbapenems, ß-lactamases, MK-0826, ß-lactams
* Corresponding author. Tel: +44-020-8200-4400; Fax: +44-020-8358-3292; E-mail: david.livermore{at}hpa.org.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Leavitt, I. Chmelnitsky, R. Colodner, I. Ofek, Y. Carmeli, and S. Navon-Venezia Ertapenem Resistance among Extended-Spectrum-{beta}-Lactamase-Producing Klebsiella pneumoniae Isolates J. Clin. Microbiol., April 1, 2009; 47(4): 969 - 974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Boselli, D. Breilh, S. Djabarouti, J. C. Bel, M. C. Saux, and B. Allaouchiche Diffusion of ertapenem into bone and synovial tissues J. Antimicrob. Chemother., October 1, 2007; 60(4): 893 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bassetti, E. Righi, R. Fasce, M. P. Molinari, R. Rosso, A. Di Biagio, M. Mussap, F. B. Pallavicini, and C. Viscoli Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum {beta}-lactamase-producing organisms in an intensive care unit J. Antimicrob. Chemother., August 1, 2007; 60(2): 433 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Burkhardt, V. Kumar, D. Katterwe, J. Majcher-Peszynska, B. Drewelow, H. Derendorf, and T. Welte Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration J. Antimicrob. Chemother., February 1, 2007; 59(2): 277 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Burkhardt, M. Brunner, S. Schmidt, M. Grant, Y. Tang, and H. Derendorf Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis J. Antimicrob. Chemother., September 1, 2006; 58(3): 632 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Chen, A. N. Nafziger, G. L. Drusano, L. Ma, and J. S. Bertino Jr. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1222 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Samuel, M. Natarajan, E. Rizkalla, D. M. Livermore, M. Warner, and P. Jenkinson Disagreements between disc diffusion, and MIC-based susceptibility categorizations of ertapenem versus ESBL producers J. Antimicrob. Chemother., November 1, 2005; 56(5): 984 - 985. [Full Text] [PDF]
|
|
|
|
|
|
K. Lolans, A. M. Queenan, K. Bush, A. Sahud, and J. P. Quinn First Nosocomial Outbreak of Pseudomonas aeruginosa Producing an Integron-Borne Metallo-{beta}-Lactamase (VIM-2) in the United States Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3538 - 3540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lemaire, F. Van Bambeke, M.-P. Mingeot-Leclercq, and P. M. Tulkens Activity of three {beta}-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus J. Antimicrob. Chemother., June 1, 2005; 55(6): 897 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Burkhardt, J. Majcher-Peszynska, K. Borner, R. Mundkowski, B. Drewelow, H. Derendorf, and T. Welte Penetration of Ertapenem Into Different Pulmonary Compartments of Patients Undergoing Lung Surgery J. Clin. Pharmacol., June 1, 2005; 45(6): 659 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore, S. Mushtaq, and M. Warner Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems J. Antimicrob. Chemother., March 1, 2005; 55(3): 306 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fluegge, S. Supper, A. Siedler, and R. Berner Antibiotic Susceptibility in Neonatal Invasive Isolates of Streptococcus agalactiae in a 2-Year Nationwide Surveillance Study in Germany Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4444 - 4446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Marchese, L. Gualco, A. M. Schito, E. A. Debbia, and G. C. Schito In vitro activity of ertapenem against selected respiratory pathogens J. Antimicrob. Chemother., November 1, 2004; 54(5): 944 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore, S. Alexander, B. Marsden, D. James, M. Warner, E. Rudd, and K. Fenton Activity of ertapenem against Neisseria gonorrhoeae J. Antimicrob. Chemother., July 1, 2004; 54(1): 280 - 281. [Full Text] [PDF]
|
|
|
|
|
|
R. N. Jones, H. K. Huynh, D. J. Biedenbach, T. R. Fritsche, and H. S. Sader Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations J. Antimicrob. Chemother., July 1, 2004; 54(1): 144 - 154. [Abstract] [Full Text] [PDF]
|
|